SEMABIZ, Inc. | ChosaReport.com

日本と海外の市場調査レポート＆サービスを取り扱っております。

RTX-GRT7039 – 変形性関節症治療薬のパイプライン

RTX-GRT7039 OSTEOARTHRITIS DRUG PIPELINE

RTX-GRT7039 - 変形性関節症治療薬のパイプライン – 市場インサイトと2032年までの予測
RTX-GRT7039 OSTEOARTHRITIS DRUG PIPELINE – MARKET INSIGHTS AND FORECASTS UPTO 2032
出版社Inkwood Research
出版年月2024年9月
ページ数46
価格タイプシングルユーザライセンス
価格USD 550
種別英文調査報告書

Report Overview

KEY INSIGHTS

RTX-GRT7039 (resiniferatoxin) is an investigational drug designed for pain relief in patients with knee osteoarthritis (OA). This highly potent agonist of the Transient Receptor Potential Vanilloid 1 (TRPV1) receptor operates through a well-established mechanism and is administered directly into the joint via intra-articular injection. As osteoarthritis patients increasingly seek effective alternatives to traditional osteoarthritis treatments, RTX-GRT7039 offers a promising option. The drug is currently being assessed in a Phase III clinical trial to evaluate its effectiveness in treating osteoarthritis pain.

The drug is developed by Grünenthal GmbH, a pharmaceutical company specializing in pain management and related conditions, including peripheral neuropathic pain, chronic post-surgical pain, chronic low back pain, osteoarthritis, and migraine. Founded in 1946 by the Wirtz family in Stolberg, Germany, Grünenthal is headquartered in Aachen, Germany. The company operates in 27 countries across Europe, Latin America, and the United States, with its products distributed in approximately 100 countries globally. Grünenthal’s mission is to strive for a world without pain, reflecting its commitment to improving lives through innovative pain management solutions.
MARKET POTENTIAL AND POSITIONING
RTX-GRT7039 (resiniferatoxin; RTX) is set to make a significant impact on the osteoarthritis treatment market, especially in knee pain management. As a powerful TRPV1 receptor agonist, RTX offers prolonged pain relief by deactivating the peripheral terminals of C- and A-delta nerve fibers. Currently undergoing Phase III clinical trials, RTX is expected to have data readouts in the latter half of 2024, with potential market authorization in the EU, US, and Japan by 2025/2026.
In May 2023, Grünenthal announced that RTX received Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration. This designation highlights RTX’s therapeutic potential as a non-opioid alternative for managing osteoarthritis pain. The designation, awarded based on promising Phase I and II data showing substantial pain relief and a favorable safety profile, expedites the drug’s development and regulatory review.

REGIONAL ANALYSIS
Inkwood Research offers an analysis of seven key markets:
• United States
• Germany
o According to the International Trade Administration, Germany’s healthcare sector is a major economic driver, employing one in six people. This sector generates an economic footprint of approximately $883 billion, accounting for about 12 percent of Germany’s GDP. This substantial investment in healthcare reflects the country’s commitment to medical innovation and patient care, which is likely to increase the demand for osteoarthritis medications.
o As Germany’s population continues to age, the prevalence of osteoarthritis is anticipated to increase, driving a greater demand for effective treatments. Given the substantial economic stake in healthcare, significant resources will be available to support the development, approval, and distribution of advanced osteoarthritis medications.
• France
• United Kingdom
• Italy
• Spain
• Japan

Table of Contents

TABLE OF CONTENTS
1. INTRODUCTION TO THE REPORT
2. RTX-GRT7039 OVERVIEW
2.1. PRODUCT DETAIL
2.2. CLINICAL DEVELOPMENT
2.2.1. CLINICAL STUDIES
2.2.2. CLINICAL TRIALS INFORMATION
2.3. OTHER DEVELOPMENTAL ACTIVITIES
2.4. PRODUCT PROFILE
3. COMPETITIVE LANDSCAPE
3.1. MARKETED THERAPIES
3.2. LATE-STAGE EMERGING THERAPIES
4. RTX-GRT7039 MARKET ASSESSMENT
4.1. MARKET OUTLOOK OF RTX-GRT7039 IN OSTEOARTHRITIS
5. 7 MAJOR MARKET’S ANALYSIS
5.1. MARKET SIZE OF RTX-GRT7039 IN THE 7 MAJOR MARKETS FOR OSTEOARTHRITIS
5.2. 7 COUNTRY ANALYSIS
5.2.1. MARKET SIZE OF RTX-GRT7039 IN UNITED STATES FOR OSTEOARTHRITIS
5.2.2. MARKET SIZE OF RTX-GRT7039 IN GERMANY FOR OSTEOARTHRITIS
5.2.3. MARKET SIZE OF RTX-GRT7039 IN FRANCE FOR OSTEOARTHRITIS
5.2.4. MARKET SIZE OF RTX-GRT7039 IN ITALY FOR OSTEOARTHRITIS
5.2.5. MARKET SIZE OF RTX-GRT7039 IN SPAIN FOR OSTEOARTHRITIS
5.2.6. MARKET SIZE OF RTX-GRT7039 IN UNITED KINGDOM FOR OSTEOARTHRITIS
5.2.7. MARKET SIZE OF RTX-GRT7039 IN JAPAN FOR OSTEOARTHRITIS
6. SWOT ANALYSIS
7. ANALYST PERSPECTIVE

List of Tables

LIST OF TABLES
TABLE 1: RTX-GRT7039, CLINICAL TRIAL DESCRIPTION, 2024
TABLE 2: RTX-GRT7039, GENERAL DESCRIPTION
TABLE 3: MARKETED THERAPIES
TABLE 4: EMERGING THERAPIES
TABLE 5: RTX-GRT7039 MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)
TABLE 6: RTX-GRT7039 MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)
TABLE 7: RTX-GRT7039 MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)
TABLE 8: RTX-GRT7039 MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)
TABLE 9: RTX-GRT7039 MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)
TABLE 10: RTX-GRT7039 MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)
TABLE 11: RTX-GRT7039 MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)
TABLE 12: RTX-GRT7039 MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

List of Figures

LIST OF FIGURES
FIGURE 1: RTX-GRT7039 MARKET SIZE IN THE 7 MAJOR MARKETS, IN $ MILLION (2019–2032)
FIGURE 2: RTX-GRT7039 MARKET SIZE IN UNITED STATES, IN $ MILLION (2019–2032)
FIGURE 3: RTX-GRT7039 MARKET SIZE IN GERMANY, IN $ MILLION (2019–2032)
FIGURE 4: RTX-GRT7039 MARKET SIZE IN FRANCE, IN $ MILLION (2019–2032)
FIGURE 5: RTX-GRT7039 MARKET SIZE IN ITALY, IN $ MILLION (2019–2032)
FIGURE 6: RTX-GRT7039 MARKET SIZE IN SPAIN, IN $ MILLION (2019–2032)
FIGURE 7: RTX-GRT7039 MARKET SIZE IN UNITED KINGDOM, IN $ MILLION (2019–2032)
FIGURE 8: RTX-GRT7039 MARKET SIZE IN JAPAN, IN $ MILLION (2019–2032)

医療・医薬の最新記事8件